small molecule

EGATEN

TRICLABENDAZOLE

Loss of exclusivityFebruary 2026FDA regulatory exclusivity expiry

CompanyNovartis →See this company's full patent-cliff portfolio

Drug detail

Brand name	EGATEN
Active ingredient	TRICLABENDAZOLE
Strength	250MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	February 2019
Marketing status	RX

Regulatory exclusivity

Code	Expires
ODE-228	February 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

Drug detail

Regulatory exclusivity

More from Novartis